Newsroom

Publications

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Read more
Publications

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Read more

Headline

MSF Foundation in Video

  • YemenUne_en
    Vidéos

    Reportage in Haydan, Yemen, on the development of the rehabilitation care in the MSF sites.

  • UneEN1year
    Vidéos

    1 year after its routine implementation, where does Antibiogo stand? Interview with Dr Nada Malou

  • AI4CC qu'est-ce que c'est
    Vidéos

    AI4CC (Artificial intelligence for cervical cancer), what is it?

News

  • Articles

    Antibiogo: facts and impacts in the fight against antimicrobial resistance

    The World Health Organization's Global AMR Awareness Week is a worldwide campaign to raise awareness and understanding of the problem of antimicrobial resistance. To mark the occasion, here is a series of infographics to help you better understand the hope that Antibiogo, a new diagnostic tool holds for combating this threat on public health.

    Read more
  • Articles

    Cervical cancer : when AI helps improve diagnosis

    Cervical cancer is the second deadliest cancer in low- and middle-income countries (1). In Malawi in East Africa, where MSF operates, over 4,000 Malawian women fall sick with cervical cancer every year. With 2,905 deaths due to cervical cancer in 2020, the country also had the second highest rate of mortality (2). How can we explain such a high mortality rate from this disease which, in high-income countries, is easily preventable and generally less deadly?  The reasons include limited access to prevention and screening, and diagnoses that are not always reliable.

     

    Clara Nordon, Director of the MSF Foundation, has just got back from a visit to Malawi with the MSF teams and tells us about the project led by the Foundation. Code name: AI4CC

    Read more

Publications

  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.